GET DAILY SIGNALSDyadic International (DYAI) Q3 2026 Earnings: Revenue Falls 61.4% but Net Loss Narrows
Key Takeaways
- Third-quarter 2026 revenue came in at $449,101, a 61.4% decline from $1,164,617 a year earlier, driven by lower grant revenue and fewer research and development (R&D) collaboration projects.
- Net loss narrowed to $1.36 million, or $(0.04) per share, compared with $1.98 million, or $(0.06) per share, in the prior-year quarter.
- Earnings per share (EPS) of $(0.04) missed the consensus estimate of $(0.03), while revenue of roughly $0.45 million fell well short of consensus near $1.43 million.
- Dyadic recorded its first direct commercial protein product sales, primarily involving recombinant transferrin and DNase I (deoxyribonuclease I), an early validation of its commercialization strategy.
- Partner Inzymes commercialized a second chymosin product, unlocking an expected $225,000 contractual payment set to be recognized in the fourth quarter of 2026.
- For additional detail on Dyadic's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for more in-depth coverage.
- Interested in automated market insights? Explore Trending AI Robots to discover data-driven trading ideas.
Why This Quarter Matters
DYAI International, Inc., now doing business as Dyadic Applied BioSolutions, is a biotechnology company focused on producing high-value recombinant proteins through its proprietary C1 and Dapibus gene expression platforms. The third quarter of 2026 carries particular weight because it represents the company's ongoing transition from a development-stage platform toward a commercial, product-driven business. Investors are watching closely whether early product launches, distribution partnerships, and profit-sharing arrangements can offset a structural decline in grant and collaboration revenue. With revenue concentrated in a handful of emerging products and partnerships, this report offers a clear gauge of how quickly Dyadic's commercialization efforts are translating into recurring sales and whether its cost discipline is keeping losses in check. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Numbers Behind the Report
For the quarter ended September 30, 2026, Dyadic reported total revenue of $449,101, down 61.4% from $1,164,617 in the same period a year earlier. The decline reflected a $538,199 drop in grant revenue tied to lower activity under Gates Foundation and CEPI (Coalition for Epidemic Preparedness Innovations) grants, along with a $187,728 decrease in R&D revenue as several collaboration projects concluded.
The company posted a net loss of $1,357,041, or $(0.04) per share, an improvement from $1,976,012, or $(0.06) per share, in the prior-year quarter. EPS of $(0.04) missed the consensus estimate of $(0.03) by one cent, while revenue of about $0.45 million fell far short of consensus estimates near $1.43 million. A non-cash gain of $545,527 from the change in fair value of a warrant liability helped cushion the bottom line.
Operating expenses declined across the board. R&D expenses fell 24.8% to $429,945, while general and administrative (G&A) expenses decreased 2.1% to $1,450,750. Loss from operations narrowed 5.9% to $1,812,365.
How the Market Responded
Dyadic's third-quarter results fell short of Wall Street's top-line expectations, with revenue of roughly $0.45 million coming in well below consensus near $1.43 million. The bottom-line result of $(0.04) per share also missed the $(0.03) consensus by a penny, though the net loss still narrowed on a year-over-year basis. Investor sentiment remains cautious: Dyadic's stock closed at $0.35 on the reporting day and has declined roughly 55% over the past three months and more than 60% over the past twelve months, reflecting broader concerns about the pace of commercialization. The revenue shortfall, driven largely by lower grant and collaboration activity, highlights the gap that emerging product sales must still fill before recurring revenue can stabilize the company's top line. From what I see, this gap underscores the importance of tracking early commercial traction closely.
What to Watch Going Forward
Looking ahead, investors should focus on whether Dyadic can convert early customer sampling into recurring orders. The company recorded its first direct commercial sales of recombinant transferrin and DNase I during the quarter, but management has acknowledged that qualification and adoption timelines are running longer than originally anticipated. The conversion of initial purchases into repeat business will be a central metric in coming quarters.
Partnership-driven revenue remains another key watch item. Partner Proliant Health and Biologicals continues to expand commercial activities around AlbuFree DX recombinant human albumin, while Inzymes has now commercialized a second chymosin product, which should generate a $225,000 payment recognized in the fourth quarter of 2026. Distribution agreements, including a new portfolio of research-use-only products launched through IBT Bioservices, add further channels for near-term revenue.
On the cost side, the company's declining R&D and G&A expenses reflect a leaner operating structure, but sustained losses mean cash runway and potential financing activity will remain important considerations. Dyadic has previously indicated that current cash resources are expected to provide runway into 2027, with disciplined spending prioritized toward high-impact programs and grant-funded activities. Margin trends, grant activity, and the cadence of new partner milestones will all shape how the market interprets the company's path toward commercial scale. I’m watching this closely as the next few quarters should clarify the pace of adoption.
Exploring AI-Powered Research Tools
In my own research process, I often rely on Tickeron’s AI Screener to quickly filter biotech names and compare fundamentals or technical signals across the sector. It helps surface ideas that might otherwise take hours to identify manually and has become a regular part of how I evaluate opportunities like DYAI.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DYAI in +4.39% Uptrend, growing for three consecutive days on October 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DYAI advanced for three days, in 181 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DYAI's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 70 cases where DYAI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for DYAI just turned positive on November 09, 2026. Looking at past instances where DYAI's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.
DYAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DYAI as a result. In 79 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for DYAI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. DYAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.703) is normal, around the industry mean (3.498). P/E Ratio (-1.618) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (52.360) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.893) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a researcher and manufacturer of genes
Industry Biotechnology
Advertisement